Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice

Cited by (154)

Items 101–154 of 154

1. The gut microbiota in neurodegenerative diseases: revisiting possible therapeutic targets for cannabidiol
   Bruna Stefane Alves de Oliveira, Debora Sandrini Milanezi, Priscila do Val Gonzaga, Fernanda Rabello Detoni, Renato Nery Soriano · 2022 · Heliyon
2. A systematic study of molecular targets of cannabidiol in Alzheimer's disease
   Nil Patil, Khushalika Patil, Mukul Jain, Arifullah Mohammed, Alpa Yadav, Parmdeep Singh Dhanda, Chittaranjan Kole, Kirtan Dave, Prashant Kaushik, Mohammad Khairul Azhar Abdul Razab et al. · 2024 · Journal of Alzheimer s Disease Reports
3. Cannabinoid Modulation of Object Recognition and Location Memory—A Preclinical Assessment
   Rose Chesworth, Georgia Watt, Tim Karl · 2018 · Handbook of behavioral neuroscience
4. Phytochemical Compounds Loaded to Nanocarriers as Potential Therapeutic Substances for Alzheimer’s Disease-Could They be Effective?
   Derya Çiçek Polat, Ayşe Esra Karadağ, Rabia Edibe Parlar Köprülü, Ioannis D. Karantas, Gökçe Mutlu, Emre Şefik Çağlar, Mehmet Evren Okur, Neslihan Üstündağ Okur, Panoraia I. Siafaka · 2022 · Current Pharmaceutical Design
5. The Neuroprotective Properties, Functions, and Roles of Cannabis sativa in Selected Diseases Related to the Nervous System
   Onesimus Mahdi, Mohamad Taufik Hidayat Baharuldin, Nurul Huda Mohd Nor, Samaila Musa Chiroma, Saravanan Jagadeesan, Mohamad Aris Mohd Moklas · 2021 · Central Nervous System Agents in Medicinal Chemistry
6. Medicinal cannabis extracts are neuroprotective against Aβ1–42‐mediated toxicity in vitro
   Dylan T. Marsh, Mayu Shibuta, Ryuji Kato, Scott Darryl Smid · 2024 · Basic & Clinical Pharmacology & Toxicology
7. Therapeutic uses of Cannabis sativa L. Current state and future perspectives
   Ana Isabel Fraguas‐Sánchez, Ana Isabel Torres‐Suárez · 2022 · Elsevier eBooks
8. Neurolipid systems: A new target for the treatment of dementia
   Gorka Pereira‐Castelo, Iker Bengoetxea de Tena, Jonatan Martínez‐Gardeazabal, Marta Moreno‐Rodríguez, Estíbaliz González de San Román, Iván Manuel, Rafael Rodríguez‐Puertas · 2024 · Basic & Clinical Pharmacology & Toxicology
9. Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer’s Disease
   Patricia Del Cerro, Carolina Alquézar, Fernando Benito Bartolomé, Pedro González-Naranjo, Concepción Pérez, Eva Carro, Juan Antonio Paez, Nuria Eugenia Campillo, Ángeles Martín‐Requero · 2018 · CNS Drugs
10. The Influence of an Acute Administration of Cannabidiol or Rivastigmine, Alone and in Combination, on Scopolamine-Provoked Memory Impairment in the Passive Avoidance Test in Mice
    Marta Kruk-Słomka, Tomasz Słomka, Grażyna Biała · 2024 · Pharmaceuticals
11. Traditional and Innovative Anti-seizure Medications Targeting Key Physiopathological Mechanisms: Focus on Neurodevelopment and Neurodegeneration
    Miriam Sciaccaluga, Gabriele Ruffolo, Eleonora Palma, Cinzia Costa · 2023 · Current Neuropharmacology
12. The Endocannabinoid System and Human Brain Functions
    John C. Ashton, Megan J. Dowie, Michelle Glass · 2017 · Elsevier eBooks
13. Combination treatment with medium dose THC and CBD had no therapeutic effect in a transgenic mouse model for Alzheimer's disease but affected other domains including anxiety-related behaviours and object recognition memory
    Beate Aumer, Rossana Rosa Porto, Madilyn Coles, Nina Ulmer, Georgia Watt, Heike Kielstein, Tim Karl · 2025 · Pharmacology Biochemistry and Behavior
14. Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer’s disease
    Samuel Ruiz de Martı́n Esteban, María T. Grande, Ana M. Martínez-Relimpio, Diego Herráez‐Aguilar, Ricardo Mostany, Cecilia J. Hillard, William H. Hind, Julián Romero · 2025 · Biomedicine & Pharmacotherapy
15. A combination of Δ9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus of an animal model of Alzheimer's disease
    Núria Sánchez-Fernández, Laura Gómez-Acero, Anna Castañé, Albert Adell, Leticia Campa, Jordi Bonaventura, Verónica Brito, Sílvia Ginés, Francisco Queiróz, Henrique Bruno Lopes Silva et al. · 2024 · Neurotherapeutics
16. Cannabinoids, the Endocannabinoid System, and Cognitive Functions: Enemies or Friends?
    Valentina F. Kitchigina · 2021 · Neuroscience and Behavioral Physiology
17. Effects of Chronic 100 mg/kg Cannabidiol Treatment in Male Double Transgenic APPSwe/PS1∆E9 Mice
    Georgia Watt, Juan C Olaya, Gerald Wolfgang Muench, Brett Garner, Tim Karl · 2026 · Pharmaceuticals
18. An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release
    Sigal Fleisher‐Berkovich, Veronica Battaglia, Francesca Baratta, Paola Brusa, Yvonne Ventura, Nitzan Sharon, Arik Dahan, Massimo Collino, Shimon Ben‐Shabat · 2023 · International Journal of Molecular Sciences
19. Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions
    João Vitor Mello-Hortega, Carolina Souza-de Oliveira, Vitória Emily Santana De Araújo, Lupe Furtado Alle, Luciane Viater Tureck, Ricardo Lehtonen Rodrigues de Souza · 2025 · European Journal of Neuroscience
20. Cannabinoids
    Sulabha Sambhaji Lalsare · 2022 · Asian Journal of Pharmaceutical Research and Health Care
21. Phytoconstituents Ameliorates Alzheimer's Disease and Cognitive Impairments: A Review of Preclinical Studies
    Vishal Kumar Biswkarma, Swati Wadhawan · 2024 · Current Bioactive Compounds
22. Long-lasting behavioral, molecular and functional connectivity alterations after chronic THC exposure during adolescence in mice
    Laura Gómez-Acero, Federico Varriano, Núria Sánchez-Fernández, Francisco Ciruela, Guadalupe Sòria, Ester Aso · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
23. Medicinal Herbs and Nutritional Supplements for Dementia Therapy: Potential Targets and Clinical Evidence
    Guido Santiago Dorman, Ignacio Flores, Carlos Gutiérrez, Ramiro Fernández Castaño, Mayra Aldecoa, Leandro M Kim · 2021 · CNS & Neurological Disorders - Drug Targets
24. O uso do Canabidiol no tratamento de doenças neurológicas selecionadas: uma revisão sistemática
    Gabriela Martins Schlesner, Cláudia Alba Natali Malagri, Daniel Luciano Gevehr, Aleteia Hummes Thaines · 2022 · Concilium
25. Alterations of THC and CBD ratios and impact on cognition
    Erica Zamberletti · 2023 · Elsevier eBooks
26. miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?
    Muhammad Wasim, Junhao Guo, Zhendong Wang, Rabia Parveen, Riling Chen, Yajun Wang, Guoda Ma · 2025 · Journal of Alzheimer s Disease Reports
27. Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease
    Chong-Lei Fu, Xuehui Li, Xiaoxing Liu, Yongbo Zheng, Xiangxian Ma, Bo Zhang, Si Xuan Chen, Lingming Hu, Sizhen Su, Xiaokun Wang et al. · 2025 · Translational Neurodegeneration
28. Cannabinoids for major neurocognitive disorder: case report and literature review
    Paula Herrera, Sergio Andrés Ochoa-Orozco, Carolina Jaramillo Toro · 2020 · Revista Colombiana de Psiquiatría
29. The effects of chronic cannabidiol administration on brain pathology and behavioral deficits found in the tau P301s-line PS19 mouse model of Alzheimer's disease
    Abigail G Nixon, Nancy S. Hong, Behroo Mirza Agha, Jackson R. Ham, Merrin Monteith, Tina Kaloa, Angela Kyriazopolus, Matt Nielsen, David R. Robertson, Andrey Golubov et al. · 2026 · Journal of Alzheimer s Disease
30. Combining cannabidiol and delta-9-tetrahydrocannabinol at a 50:3 ratio – a new therapeutic strategy for APPSwe/PS1ΔE9 transgenic mice?
    Madilyn Coles, Rossana Rosa Porto, Rose Chesworth, Genevieve Z. Steiner-Lim, Tim Karl · 2026 · Neurobiology of Aging
31. Phytocannabinoids: a new frontier in Alzheimer’s disease management
    Jagadeesh Sridhara Rao · 2024 · Academia Biology
32. Endocannabinoids and Alzheimer's disease
    Chu Chen · 2025 · Handbook of behavioral neuroscience
33. Dementia: Alzheimer’s Disease
    Kylie O’Brien, Philip Blair · 2021 · Springer eBooks
34. Revisão integrativa: verificação da eficácia / efetividade da Cannabis medicinal e dos derivados canabinoides na Doença de Alzheimer
    Poliana Zanoni de Moraes, André Rinaldi Fukushima, María Aparecida Nicoletti · 2022 · Revista Fitos
35. Cannabinoids for major neurocognitive disorder: case report and literature review
    Paula Herrera, Sergio Andrés Ochoa-Orozco, Carolina Jaramillo Toro · 2021 · Revista Colombiana de Psiquiatría (English ed )
36. Medicinal Cannabis for Alzheimer's Disease
    Genevieve Z. Steiner, Madilyn Coles, Kayla M. Jaye, Najwa‐Joelle Metri, Ali S Butt, Katerina Christofides, Jackson McPartland, Zainab Al-Modhefer, Diana Karamacoska, Ethan B. Russo et al. · 2023 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
37. Sisyphus in Neverland
    Isidró Ferrer · 2017 · Journal of Alzheimer s Disease
38. Canabidiol como opção terapêutica na Doença de Alzheimer
    Fabiana Teixeira Aguiar, Jéssica de Vasconcellos Barbosa, Lays Cristina da Silva, Marcela Maria Pereira de Lemos Pinto Moura, Juliana Prado Gonçales · 2024 · Brazilian Journal of Health Review
39. Creation of single App knock-in mouse models and of single MAPT knock-in models: Demonstration of Aβ-tau axis
    Takaomi C. Saido · 2024 · Elsevier eBooks
40. In vivo and in vitro assays, and safety profiles of cannabinoids
    Mayeso N.V. Gwedela, Collins Edward Jana, Tuntufye Mwambyale, Ibrahim Chikowe, Lifa Chimphepo, George Chirambo · 2024 · Elsevier eBooks
41. The chemistry and pharmacology of tetrahydrocannabinol and cannabidiol
    Collins Edward Jana, Tuntufye Mwambyale, George Chirambo, Mayeso N.V. Gwedela, Lifa Chimphepo, Ibrahim Chikowe · 2024 · Elsevier eBooks
42. Long-lasting behavioral, molecular and functional connectivity alterations after chronic exposure to THC in adolescent mice
    Ester Aso, Laura Gómez-Acero, Federico Varriano, Núria Sánchez-Fernández, Francisco Ciruela, Guadalupe Sòria · 2024 · Research Square
43. Effects of THC-rich Cannabis sativa extract on Biochemical Parameters in Obesity
    Ana Beatriz Costa, Bruna Barros Fernandes, Cristini da Rosa Turatti, Thalya Seifer Souza, Thais Medeiros de Jesus, Larissa Espindola da Silva, Mariana Pacheco de Oliveira, Mariella Reinol da Silva, Nicole Alessandra Engel, Daniéle Hendler Salla et al. · 2024 · Research Square
44. O uso terapêutico do canabidiol em crianças com Transtorno do Espectro Autista: uma revisão sistemática
    Tiago Porfírio Teixeira, Leonardo Augusto Lombardi, Irene Lustosa Dias, Laura Ayumi Rodrigues Okamura, Jéssica Câmara Guimarães, Yasmin Corrêa Vasconcellos, Geovanna Garcia Teixeira, Yuri Christian Justino Alves de Sousa, Juliana Beatriz Espindula Raizel, Ana Silva et al. · 2024 · Revista Sociedade Científica
45. Targeting Cannabinoid Receptors Against Neurodegenerative Diseases: NanoLuc Binary Technology and Proximity Ligation In Situ Assay to Evaluate Pharmacological Activity of Novel Compounds and Receptor Heteromerization
    Núria Sánchez-Fernández, Laura Gómez-Acero, Francisco Ciruela, Ester Aso · 2024 · Neuromethods
46. A Self-Emulsifying Nanococktail of Pomegranate and Cannabidiol Reduces Cognitive Decline in Mice
    Oded Shoseyov, Avi Palatnik, Maayan Dadon‐Freiberg, Orit Dagan, Ronit Shaltiel‐Karyo · 2025 · Nutrition and Dietary Supplements
47. Cannabidiol/tetrahydrocannabinol-enrich extract decreases neuroinflammation and improves locomotor outcome following spinal cord injury
    Julián Del Core, Ignacio Jure, Fresia Melina Silva Sofrás, Luciana Pietranera, Santiago Ronchetti, Paulina Roig, Martín F. Desimone, Alejandro Federico De Nicola, Florencia Labombarda · 2025 · Neuroscience
48. O USO DA CANNABIS MEDICINAL NO TRATAMENTO DA DOENÇA DE ALZHEIMER: ATRIBUIÇÕES DO FARMACÊUTICO E A INTER PROFISSIONALIDADE NO CUIDADO
    Sabrina Bartz Pereira, Wendel Silva de Souza, Anna Maly de Leão e Neves Eduardo · 2025
49. FIGURES 45. Axinyssa djiferi spec. nov. 4 in A new species of Axinyssa Lendenfeld, 1897 (Porifera, Demospongiae, Halichondrida) from the Senegalese coast
    Nicole Boury‐Esnault, Christian Marschal, Probst, Jean-Michel Korn-, Gilles Barnathan · 2002 · INFM-OAR (INFN Catania)
50. Phytochemical and biological research of Cannabis pharmaceutical resources
    Da-Cheng Hao, Pei Gen Xiao · 2026 · Elsevier eBooks
51. Demenz: Alzheimerkrankheit
    Kylie O’Brien, Philip Blair · 2026 · Springer eBooks
52. Phytocannabinoid cannabidiol (CBD) in neurodegenerative diseases: From polypharmacology to drug development
    Bingxing Zhang, Jiang Nan, Yunfei Zhang, Boxin Zhang, Changhua Ke, Wen Wang, Teng Wu, Juan Xia, Furong Yang, Meiling He et al. · 2026 · European Journal of Medicinal Chemistry
53. Microglial Therapeutic Potential in Alzheimer’s Disease: From Phenotypic Diversity to Targeted Interventions
    Maria-Raluca Gogu, Ivona Costăchescu, Gabriela Dumitriţa Stanciu, Bogdan-Ionel Tamba, Mitică Ciorpac, Lucian Gorgan · 2026 · Pharmaceuticals
54. Cannabidiol in Alzheimer’s disease: evidence-weighted molecular mechanisms and translational challenges
    Sreenivasulu Sura, Saravanan Jagadeesan, Siti Saleha Masrudin, Mohamad Aris Mohd Moklas, Nurul Huda Mohd Nor · 2026 · Molecular Biology Reports